Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lomitapide + atorvastatin
- Development stage
- Phase 2
- Lead developer
- Chiesi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lomitapide (AEGR-733) is a small molecule inhibitor of microsomal triglyceride-transfer protein (MTP), developed for the treatment of dyslipidemia, particularly in patients with homozygous familial hypercholesterolemia. By inhibiting MTP, lomitapide reduces the production of lipoproteins in the intestine and liver, thereby lowering blood levels of cholesterol and triglycerides. Atorvastatin is an HMG-CoA reductase inhibitor (statin) that decreases cholesterol synthesis in the liver to reduce LDL cholesterol and triglycerides while increasing HDL cholesterol. The combination has been studied for additive or synergistic effects on lipid lowering in patients with high cholesterol who do not reach target LDL-C levels with statins alone[1][2][6][7][8].
- Other names
- lomitapide mesylate + atorvastatin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)MTTP (Microsomal triglyceride transfer protein large subunit)
Beyond the preview
Go deeper on lomitapide + atorvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lomitapide + atorvastatin.